Andreas berheide / Shutterstock.com
The Dutch lobby to amend Directive 98/44/EC on the legal protection of biotechnological inventions will severely damage the ability of the biotech sector to innovate—and for no tangible reason, says Annemiek Verkamman of HollandBIO.
Life sciences and biotechnology are delivering treatments for an increasing number of unmet medical needs, while infectious diseases are being eradicated through innovative vaccines. Proper protection of intellectual property is a crucial factor for meeting the needs of our society in the near future.
By announcing her intention to amend Directive 98/44/EC on the legal protection of biotechnological inventions in order to benefit just a few Dutch breeders, the Dutch minister for agriculture, Sharon Dijksma, is directly leaving the 600 innovative biotech companies in the Netherlands out in the cold. Amending the biotech directive will block innovation and diminish the global position of the whole European biotech sector. What is the motivation for the change? To solve an alleged problem that is solely based on fear and fable.
Dutch life sciences sector is booming
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
European Patent Office
George Washington Law School
Kirkland & Ellis International LLP
Marks & Clerk
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
The United States Patent and Trademark Office (USPTO)
World Intellectual Property Office
For multi-user price options, or to check if your company has an existing subscription we can add you into for FREE, please contact Atif at firstname.lastname@example.org.
If you have any technical issues please email tech support.
HollandBIO, biotechnology, R&D, IP, patent, ILP, EPO, Annemiek Verkamman, plant breeders,